Table 1.
Characteristics of the internal and external cohorts with unresectable PDAC
| Internal cohort (n = 203) | External validation cohort (n = 22) | |
|---|---|---|
| Age, years | ||
| Mean | 64.2 | 61.4 |
| Range | 30-90 | 38-78 |
| Sex, n (%) | ||
| Male | 111 (54.7) | 14 (63.6) |
| Female | 92 (45.3) | 8 (36.4) |
| AJCC stage, n (%) | ||
| II | 7 (3.4) | 0 (0) |
| III | 28 (13.8) | 0 (0) |
| IV | 168 (82.8) | 22 (100) |
| Liver metastasis, n (%) | ||
| Yes | 131 (64.5) | 22 (100) |
| No | 72 (35.5) | 0 (0) |
| Chemotherapy, n (%) | ||
| FOLFIRINOX | 59 (29.1) | 14 (63.6) |
| FOLFOXIRI | 26 (12.8) | 0 (0) |
| FOLFOX | 14 (6.9) | 1 (4.5) |
| Gemcitabine + nab-paclitaxel | 41 (20.2) | 5 (22.7) |
| Gemcitabine | 20 (9.9) | 1 (4.5) |
| Gemcitabine + oxaliplatin | 13 (6.4) | 0 (0) |
| Other | 7 (3.4) | 1 (4.5) |
| None at our institute | 23 (11.3) | 0 (0) |
| Median survival time, months (95% CI) | 6.7 (5.8-8.6) | 8.4 (3.8-10.2) |
| Censored, n (%) | 17 (8.4) | 0 (0) |
AJCC, American Joint Committee on Cancer; CI, confidence interval; PDAC, pancreatic ductal adenocarcinoma.